Articles tagged with Cervical Cancer
Researchers at Case Western Reserve University found a new combination therapy, called chemoradiation, that increases survival rates by 50% for cervical cancer patients. The treatment combines radiation with platinum-based chemotherapy agents, leading to more effective cancer cell killing and lower side effects.
A new study predicts that regular anal Pap smear screenings can lead to early detection of pre-cancerous lesions and treatment of anal squamous cell cancer among high-risk men. The screening is estimated to be cost-effective, saving an average of $16,000 per year of life gained.
A new test using vinegar and visual inspection detected over 75% of potential cancers among African study participants, identifying almost twice as many cases as Pap smears. The inexpensive and easy test could provide a reliable screening option for women in developing countries where cervical cancer is prevalent.
A landmark study involving women with invasive cervical cancer showed that adding chemotherapy to radiation therapy significantly improves survival rates and disease-free survival. The study found that 73% of patients who received both treatments survived for at least five years, compared to 58% of those given only radiation.
A common surfactant, sodium dodecyl sulfate (SDS), has been shown to inactivate sexually transmitted viruses including human immunodeficiency virus (HIV) and human papillomaviruses (HPVs). The discovery provides a major step towards developing a practical, non-toxic, and inexpensive product to protect women from HPV infection.
Researchers use infrared spectroscopy to analyze over 2,000 individual cervical cells from women with dysplasia and cervical cancer, finding that normal-looking cells have distinct abnormal spectra. This could simplify Pap test evaluation and lead to earlier cancer detection and prevention.
Researchers found that women with the p53Arg gene variation are seven times more likely to develop cervical cancer due to HPV infection. The study suggests that this genetic variation may confer a strong susceptibility to skin cancers linked to HPV and ultra-violet radiation exposure.
Researchers have discovered that killer lymphocytes recognising HPV can be found in tumour tissues, and that they may be able to boost the immune system's response to prevent cancer. A novel vaccine is also being developed to stimulate killer lymphocytes to target HPV-infected cells.
The vaccine aims to prevent HPV-related warts and cervical cancer in women, with 5,000 deaths occurring annually in the US. The study will verify safety and immune response, paving the way for a broader vaccine protecting against multiple HPV types.